IN2014KN01304A - Improved synergistic anti diabetic compositions - Google Patents

Improved synergistic anti diabetic compositions

Info

Publication number
IN2014KN01304A
IN2014KN01304A IN1304/KOLNP/2014A IN1304KON2014A IN2014KN01304A IN 2014KN01304 A IN2014KN01304 A IN 2014KN01304A IN 1304KON2014 A IN1304KON2014 A IN 1304KON2014A IN 2014KN01304 A IN2014KN01304 A IN 2014KN01304A
Authority
IN
India
Prior art keywords
compositions
metabolites
concerned
derivatives
improved synergistic
Prior art date
Application number
IN1304/KOLNP/2014A
Inventor
Nick Naser Gorgani
Original Assignee
Ozstar Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011904887A external-priority patent/AU2011904887A0/en
Application filed by Ozstar Therapeutics Pty Ltd filed Critical Ozstar Therapeutics Pty Ltd
Publication of IN2014KN01304A publication Critical patent/IN2014KN01304A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention is concerned with improved synergistic compositions effective in the treatment of diabetes and/or hyperglycemia. In particular the present invention is concerned with synergistic compositions comprising inulin preparations having a defined degree of polymerisation (DP) of below about 25 and sulfonylureas and/or a sulfonamide and/or derivatives and/or metabolites thereof used in the treatment of Type 2 Diabetes Meliitus (T2DM). Said compositions are also used for preventing the development of or ameliorating side effects or conditions in a subject treated with sulfonylurea and/or a sulfonamide compounds (and/or derivatives and/or metabolites thereof or combinations thereof) said side effects including hypoglycemia gastrointestinal disturbances fatigue weight gain and satiety.
IN1304/KOLNP/2014A 2011-11-23 2014-06-19 Improved synergistic anti diabetic compositions IN2014KN01304A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2011904887A AU2011904887A0 (en) 2011-11-23 Improved synergistic anti-diabetic compositions
AU2012902723A AU2012902723A0 (en) 2012-06-27 Improved synergistic anti-diabetic compositions -II
PCT/AU2012/001442 WO2013075172A1 (en) 2011-11-23 2012-11-23 Improved synergistic anti-diabetic compositions

Publications (1)

Publication Number Publication Date
IN2014KN01304A true IN2014KN01304A (en) 2015-10-16

Family

ID=48468910

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1304/KOLNP/2014A IN2014KN01304A (en) 2011-11-23 2014-06-19 Improved synergistic anti diabetic compositions

Country Status (11)

Country Link
US (1) US9737559B2 (en)
EP (1) EP2782586A4 (en)
JP (2) JP2014533702A (en)
KR (1) KR102104384B1 (en)
CN (1) CN104244958B (en)
AU (1) AU2012343332B2 (en)
BR (1) BR112014012401A2 (en)
CA (1) CA2861661C (en)
IN (1) IN2014KN01304A (en)
RU (1) RU2642633C2 (en)
WO (1) WO2013075172A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109498611B (en) * 2019-01-15 2020-09-01 张惊宇 Medicine for treating diabetic peripheral neuralgia and application thereof
RU2741079C1 (en) * 2020-04-06 2021-01-22 Общество С Ограниченной Ответственностью "Технологии Дкв" Prebio dkv food additive

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082842A (en) * 1975-02-21 1978-04-04 Armando Nahle Medicant composition for the treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
ES2206821T3 (en) * 1997-06-23 2004-05-16 Societe Des Produits Nestle S.A. USE OF A NUTRITIVE COMPOSITION FOR THE PREPARATION OF A LIQUID COMPOSITION FOR DIABETICS.
US20030130205A1 (en) * 2000-04-12 2003-07-10 Christian Samuel T. Novel pharmaceutical anti-infective agents containing carbohydrate moieties and methods of their preparation and use
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
WO2004070009A2 (en) * 2003-01-31 2004-08-19 Targesome Inc. Targeted multivalent macromolecules
BRPI0415781A (en) * 2003-10-27 2006-12-26 Innodia Inc Method for treating diabetes in a patient and pharmaceutical kit
JP2006052191A (en) * 2004-08-16 2006-02-23 Taiyo Kagaku Co Ltd Composition for preventing, ameliorating or treating diabetes
CN1861173A (en) * 2005-05-13 2006-11-15 王锦 Edible cellulose powder used as nutrient therapy medicine for diabetic
WO2006138705A1 (en) * 2005-06-17 2006-12-28 Henry H Ottens Manufacturing Company, Inc Fiber fortified cereals, cereal bars and snacks and methods for making
ES2706281T3 (en) * 2005-12-20 2019-03-28 Nutricia Nv Composition of carbohydrates and decreased glucose response
EP2146680B1 (en) * 2007-05-10 2011-10-19 L'Oréal Cosmetic composition comprising an inulin derivative in the form of an emulsion expanded in volume
US20090214511A1 (en) * 2008-02-21 2009-08-27 Trung Hong Tran Digestible compositions of inulin for managing blood glucose levels
GB0907019D0 (en) * 2009-04-24 2009-06-03 Oxford Nutrascience Ltd Pharmaceutical,therapeutic or nutritional delivery systems for functional ingredients
ES2578081T5 (en) * 2009-05-01 2019-10-16 Uas Laboratories Llc Bacterial compositions for prophylaxis and treatment of degenerative diseases
CN103025334B (en) * 2010-05-24 2016-03-16 澳星医疗私人有限公司 Anti-diabetic composition and method

Also Published As

Publication number Publication date
JP2014533702A (en) 2014-12-15
CN104244958B (en) 2017-11-17
RU2642633C2 (en) 2018-01-25
AU2012343332A1 (en) 2014-07-17
KR102104384B1 (en) 2020-04-27
AU2012343332B2 (en) 2017-03-16
EP2782586A4 (en) 2015-07-01
CA2861661A1 (en) 2013-05-30
US9737559B2 (en) 2017-08-22
US20140303118A1 (en) 2014-10-09
BR112014012401A2 (en) 2017-06-13
JP6609287B2 (en) 2019-11-20
WO2013075172A1 (en) 2013-05-30
RU2014125249A (en) 2015-12-27
CN104244958A (en) 2014-12-24
CA2861661C (en) 2021-03-16
JP2017226672A (en) 2017-12-28
KR20150002575A (en) 2015-01-07
EP2782586A1 (en) 2014-10-01

Similar Documents

Publication Publication Date Title
PH12018500767A1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2013004699A (en) Pharmaceutical combinations for the treatment of metabolic disorders.
WO2011127304A3 (en) Methods of treating an overweight subject
MX339614B (en) Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2.
EA201490982A1 (en) ANALOGUE GLUACAGONA
MX2013003034A (en) Piperidinyl-substituted lactams as gpr119 modulators.
WO2010126626A3 (en) Dual mechanism inhibitors for the treatment of disease
NZ592283A (en) Combination of an insulin and the GLP-1 agonist AVE0010
WO2013186240A3 (en) Exendin-4 peptide analogues
EP3434687A3 (en) Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same
WO2012054526A8 (en) Chemosensory receptor ligand-based therapies
WO2010123930A3 (en) Chemosensory receptor ligand-based therapies
EP2560660A4 (en) Chemosensory receptor ligand-based therapies
WO2013103919A8 (en) Compositions and methods for treating metabolic disorders
WO2012051567A3 (en) Obesity-related genes and their proteins and uses thereof
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
WO2013173417A3 (en) Glucokinase activator compositions for the treatment of diabetes
NZ603614A (en) Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator
WO2011056447A3 (en) Methods and kits for preventing hypoglycemia
WO2009045291A3 (en) Mast cell stabilizers in the treatment of obesity
IN2014KN01304A (en) Improved synergistic anti diabetic compositions
WO2012054527A3 (en) Chemosensory receptor ligand-based therapies
TN2010000566A1 (en) Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
WO2012054528A3 (en) Chemosensory receptor ligand-based therapies
EA201391063A1 (en) APOLIPOPROTEIN A-IV AS ANTIDIABETIC PEPTIDE